Navigation Links
New drug, Vemurafenib, doubles survival of metastatic melanoma patients
Date:3/1/2012

A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib increasing median survival from about 6 months to 15.9 months. In patients who responded, the drug stopped cancer progression for a median 6.7 months.

"For melanoma patients with a BRAF V600 mutation, this drug is a breakthrough. Not a cure, but a major breakthrough," says Karl Lewis, MD, investigator at the University of Colorado Cancer Center, associate professor at the University of Colorado School of Medicine, and one of the study's authors.

Lewis notes that until about 18 months ago, no drug existed for metastatic melanoma the most dangerous form of skin cancer that was proven to extend survival past that of patients who chose not to treat the disease. The CU Cancer Center is a leading treatment center for metastatic melanoma, and has been instrumental in enrolling patients in trials of this new category of melanoma drugs BRAF inhibitors.

The BRAF mutation is a known oncogene a gene that when mutated causes cancer. Specifically, the BRAF V600 mutation signals a cell to grow without bounds. Vemurafenib is a BRAF inhibitor. The mutation turns cancer on and Vemurafenib turns it off.

And turning off BRAF in the approximately 100,000 patients diagnosed worldwide each year with BRAF-positive metastatic melanoma more than doubles their time of survival.

"Rarely do we see results this dramatic," says Lewis. "This represents a new standard of care for patients with metastatic melanoma harboring a BRAF mutation."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Page: 1

Related medicine news :

1. DOE laboratories help develop promising new cancer fighting drug, vemurafenib
2. Mental Disorders Linked to Drug, Alcohol Abuse in U.S. Vets
3. New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients
4. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
5. Cancer Risk Doubles After Organ Transplant, Study Finds
6. Capacity to diagnose osteoporosis doubles in Armenia
7. ADHD Doubles a Childs Risk of Injury: Study
8. Bone marrow transplant survival more than doubles for young high-risk leukemia patients
9. EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
10. Sitting for long periods doubles risk of blood clots in the lungs
11. Text message support for smokers doubles quit rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... has selected ezDI’s computer-assisted coding (CAC) software for its Clinical Documentation Improvement (CDI) ... ezNLP, and a patent pending ICD-10 solution - ezCAC is an enterprise-level coding ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Castle Dermatology Institute ... practice. Dr. Pedram Ghasri is a graduate of the University of California, Los Angeles. ... his studies at the University of California, Irvine Medical School. As a nationally recognized ...
(Date:8/31/2015)... ... August 31, 2015 , ... “My mother and husband ... inventor, from Hagerhill, Ky. “I thought there could be a comfortable way to prevent ... The Nasal Cannula Ear Protector offers a more secure way to anchor the cannula ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... A year ... the team is preparing to release a new issue commemorating the successful first year. ... information they need for a potentially difficult time in their lives,” says Melissa Wolfert, ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s big news for ... the digital healthcare industry. , Consumer driven health plans (CDHPs) are a growing ... advisory and strategic role to the company, and another to answer customers’ questions directly. ...
Breaking Medicine News(10 mins):Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 3Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3
... Mountain View, CA December 5, 2008 ... on developing technologies and products for immune disorders, ... therapeutic treatment for Graft versus Host Disease (GvHD) ... being held December 6 through 9 in San ...
... pseudoephedrine for kids under 2 poses toxicity issues because ... -- Exposure to the decongestant pseudoephedrine, found in many ... among children in the United States. , This is ... the highest risk for toxicity and for whom safe ...
... a USGS study released today,showing that man-made chemicals remained ... the Water Quality Association is encouraging consumers,to educate themselves ... According to a report by the U.S. Geological ... removed by public treatment processes. The,USGS examined water ...
... Launched by Product Stewardship Institute and King Pharmaceuticals ... 5 /PRNewswire-USNewswire/ - - The Product Stewardship ... Dialogue Meeting earlier this week in Washington, DC ... medications to combat increasing rates of prescription drug abuse, ...
... AIDS-causing virus don,t get sick , , FRIDAY, Dec. 5 (HealthDay ... of how a small number of HIV-infected people manage to ... medicine. , The key seems to be an unusual feature ... hope it might lead to better drug therapies or even ...
... another reason to quit smoking, consider that it may diminish ... the University of Rochester Medical Center have found that women ... were significantly more likely to face fertility problems and suffer ... non-smoking women showed those who were exposed to second hand ...
Cached Medicine News:Health News:Decongestant Exposure Needs Closer Look 2Health News:Chemicals Remain in Most Treated Water, Says Report 2Health News:Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications 2Health News:Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications 3Health News:Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications 4Health News:Special Immune Cells May Be Key to HIV Resistance 2Health News:Secondhand smoke raises odds of fertility problems in women 2
(Date:8/28/2015)... Aug. 28, 2015  Delays in the launch ... slow down the decision-making process, resulting in missed ... critical for biopharmaceutical companies to develop a tactical ... for quicker and more meaningful insights. ... LLC, nearly three-quarters of benchmarked study participants use ...
(Date:8/28/2015)... According to a new market ... Prostate) Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... 17,689.0 Million USD by 2020 at a CAGR of ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/686gwf/investigation ... Report on China,s Bevacizumab Market ,2010-2019" report to ... trade name of Avastin, bevacizumab injection is the first ... was approved by CFDA to treat metastatic colorectal cancer. ... all come from Roche and its subsidiary Genectech. ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Bevacizumab Market 2015-2019 2
... 15 Omega 3 fatty acids bound to,phospholipids ... natural,alternative and may have beneficial effect on impulsivity ... While several studies have reported,beneficial effects of omega-3 ... have specific positive effects on,impulse control., These ...
... May 14 Biopure Corporation,(Nasdaq: BPUR ... its Phase II coronary,revascularization trial have been ... is entitled "Proof-of-concept trial to,evaluate haemoglobin based ... protocol design, and haemodynamic,results." The manuscript was ...
Cached Medicine Technology:Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 2Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 3
... a two chain (alpha- and beta-subunits) glycoprotein ... the placenta and is normally found in ... the trophoblastic epithelium of the placenta, hCG ... the early stages of pregnancy. The primary ...
... for movement is critical ... wheelchairs. Thats why this ... technology to do just ... state-of-the-art technology, these wheelchair ...
When patients are less mobile our ProPlus™ Stand-On Scale with built-in wheels moves easily to them. Extremely durable and safe, the easy grip handrail and non-skid platform provide added suppo...
... 100 provides a new screening, diagnostic, treatment ... medical management of sleep-related breathing disorders. The ... unmet need for an ambulatory, reliable, patient ... to the great number of OSA sufferers, ...
Medicine Products: